Hydromorphone Hydrochloride Tablet
FDA Label NDC 0406-3243

53 label sections · Submitted to the FDA by Specgx Llc · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Specgx Llc for the product Hydromorphone Hydrochloride (NDC 0406-3243). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: serious and life-threatening risks from use of hydromorphone hydrochloride tablets, 1 indications and usage, 2.1 important dosage and administration instructions, 2.2 patient access to an opioid overdose reversal agent for the emergency treatment of opioid overdose, 2.3 initial dosage, 2.4 dosage modifications in patients with hepatic impairment, 2.5 dosage modifications in patients with renal impairment, 2.6 titration and maintenance of therapy, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

* Please review the disclaimer below.